Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis
Adult Vaccines Market is expected to be close to US$ 20 Billion by the year 2022. Because of vaccines, some diseases (like Polio and Diphtheria) are becoming rare. Vaccination can prevent certain deadly diseases in all age groups. Almost all countries around the world have introduced efficient National Immunization Programme in their vaccination schedule to overcome the epidemics caused by vaccine-preventable diseases. WHO’s Global Vaccine Action Plan, Global Immunization Vision and Strategy (GIVS), The GAVI Alliance all are putting their best to minimize the incidence of vaccine-preventable diseases which indeed is driving the adult vaccine market vigorously.
Influenza Vaccine Leads the Adult Vaccine Market for the Year 2017
Influenza vaccine is dominating the adult vaccine segment in year 2017, however it will lose its place to Pneumococcal vaccine in the coming future as admissions for pneumonia had almost tripled over the last 15 years. Other than Influenza and Pneumococcal Vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines also have considerable market share in adult vaccines market.
Considerable Growth in Immunization of Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV Vaccines
In terms of Immunization; Influenza holds the maximum share as influenza vaccination is recommended to take annually in almost all countries of the world. However, with the growing awareness and efficiency of vaccines in preventing diseases, our analysis found that there will be considerably growth in the number for people opting for Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV vaccines in future till 2022.
Administration of Vaccines Doses
Influenza Vaccine holds the topmost place while talking about the administration of vaccine doses as influenza strains change every year and people needs to get an updated influenza shot each year to stay protected. Expect Influenza; Cervical Cancer (HPV), Pneumococcal and Hepatitis vaccines have remarkable administration doses.
Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis is the 2nd publication by Renub Research on Adult Vaccines Market. This 181 pages research report with 77 Figures and 32 Tables provides a complete analysis of Adult Vaccines Market, Immunization Numbers in People, Number of Vaccine Doses Administered in Adults (Disease wise) & Key Players Analysis.
Adult Vaccines in the Report have been studied from 3 Viewpoints
1. Global Adult Vaccines (Disease wise) Market & Forecast (2011 – 2022)
2. People Immunized (Disease wise) & Forecast (2011 – 2022)
3. Doses of Vaccines Administered (Disease wise) & Forecast (2011 – 2022)
Vaccines Studied in the Report are as Follows:
1. Influenza
2. Cervical Cancer
3. Zoster (Shingles)
4. MMRV (Measles, Mumps, Rubella and Varicella)
5. Pneumonia
6. Meningitis
7. Hepatitis
8. DTap (Diphtheria, Tetanus, Pertussis)
9. Travel & Miscellaneous Vaccine
Companies Vaccines Sales and Forecast
1. GlaxoSmithKline, plc Sales & Forecast (2011 – 2022)
2. Merck & Co. Sales & Forecast (2011 – 2022)
3. Sanofi Pasteur’s Sales & Forecast (2011 – 2022)
4. Pfizer, Inc.’s Sales & Forecast (2011 – 2022)
5. Others Vaccines
Key Questions Answered In This Report
Influenza Vaccine Leads the Adult Vaccine Market for the Year 2017
Influenza vaccine is dominating the adult vaccine segment in year 2017, however it will lose its place to Pneumococcal vaccine in the coming future as admissions for pneumonia had almost tripled over the last 15 years. Other than Influenza and Pneumococcal Vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines also have considerable market share in adult vaccines market.
Considerable Growth in Immunization of Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV Vaccines
In terms of Immunization; Influenza holds the maximum share as influenza vaccination is recommended to take annually in almost all countries of the world. However, with the growing awareness and efficiency of vaccines in preventing diseases, our analysis found that there will be considerably growth in the number for people opting for Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV vaccines in future till 2022.
Administration of Vaccines Doses
Influenza Vaccine holds the topmost place while talking about the administration of vaccine doses as influenza strains change every year and people needs to get an updated influenza shot each year to stay protected. Expect Influenza; Cervical Cancer (HPV), Pneumococcal and Hepatitis vaccines have remarkable administration doses.
Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis is the 2nd publication by Renub Research on Adult Vaccines Market. This 181 pages research report with 77 Figures and 32 Tables provides a complete analysis of Adult Vaccines Market, Immunization Numbers in People, Number of Vaccine Doses Administered in Adults (Disease wise) & Key Players Analysis.
Adult Vaccines in the Report have been studied from 3 Viewpoints
1. Global Adult Vaccines (Disease wise) Market & Forecast (2011 – 2022)
2. People Immunized (Disease wise) & Forecast (2011 – 2022)
3. Doses of Vaccines Administered (Disease wise) & Forecast (2011 – 2022)
Vaccines Studied in the Report are as Follows:
1. Influenza
2. Cervical Cancer
3. Zoster (Shingles)
4. MMRV (Measles, Mumps, Rubella and Varicella)
5. Pneumonia
6. Meningitis
7. Hepatitis
8. DTap (Diphtheria, Tetanus, Pertussis)
9. Travel & Miscellaneous Vaccine
Companies Vaccines Sales and Forecast
1. GlaxoSmithKline, plc Sales & Forecast (2011 – 2022)
2. Merck & Co. Sales & Forecast (2011 – 2022)
3. Sanofi Pasteur’s Sales & Forecast (2011 – 2022)
4. Pfizer, Inc.’s Sales & Forecast (2011 – 2022)
5. Others Vaccines
Key Questions Answered In This Report
- What will be the Market Size of Global Adult Vaccine by the year 2022?
- What are the Key Drivers & Challenges for Adult Vaccines Market?
- Who are the key players in Adult Vaccine Market?
- What products are in key Players Pipeline?
1 RESEARCH FINDINGS
2 GLOBAL – ADULT VACCINES MARKET AND FORECAST
3 GLOBAL – ADULT VACCINES MARKET SHARE AND FORECAST
4 WORLDWIDE – ADULT IMMUNIZED NUMBERS AND FORECAST
5 WORLDWIDE – ADULT IMMUNIZED SHARE AND FORECAST
6 WORLDWIDE – DOSES OF ADULT VACCINES ADMINISTERED AND FORECAST
7 WORLDWIDE – DOSES OF VACCINES ADMINISTERED TO ADULT SHARE AND FORECAST
8 WORLDWIDE – VACCINE COMPANIES MARKET SHARE AND FORECAST
9 DISEASE WISE – ADULT VACCINES MARKET AND FORECAST
9.1 Influenza – Adult Vaccines Market and Forecast
9.2 Cervical Cancer (HPV) – Vaccines Market and Forecast
9.3 Zoster (Shingles) – Vaccines Market and Forecast
9.4 MMRV (Measles, Mumps, Rubella, and Varicella Vaccine) – Adult Vaccines Market and Forecast
9.5 Pneumococcal – Adult Vaccines Market and Forecast
9.6 Meningococcal – Adult Vaccines Market and Forecast
9.7 Hepatitis – Adult Vaccines Market and Forecast
9.8 TdaP – Adult Vaccines Market and Forecast
9.9 Travel and Miscellaneous – Vaccines Market and Forecast
10 DISEASE WISE – ADULT IMMUNIZED NUMBERS AND FORECAST
10.1 Influenza – Number of Adults Immunized and Forecast
10.2 Cervical Cancer (HPV) – People Immunized and Forecast
10.3 Zoster (Shingles) – Number of People Immunized and Forecast
10.4 MMRV – Number of Adults Immunized and Forecast
10.5 Pneumococcal – Number of Adults Immunized and Forecast
10.6 Meningococcal – Number of Adults Immunized and Forecast
10.7 Hepatitis – Number of Adults Immunized and Forecast
10.8 TdaP – Number of Adults Immunized and Forecast
11 DISEASE WISE – DOSES OF VACCINES ADMINISTERED AND FORECAST
11.1 Influenza – Doses of Adult Vaccines Administered and Forecast
11.2 Cervical Cancer (HPV) – Doses of Vaccines Administered and Forecast
11.3 Zoster (Shingles) – Doses of Vaccines Administered and Forecast
11.4 MMRV – Doses of Adult Vaccines Administered and Forecast
11.5 Pneumococcal – Doses of Adult Vaccines Administered and Forecast
11.6 Meningococcal – Doses of Adult Vaccines Administered and Forecast
11.7 Hepatitis – Doses of Adult Vaccines Administered and Forecast
11.8 TdaP – Doses of Adult Vaccines Administered and Forecast
12 DISEASE WISE - IMMUNIZATION PROFILE
12.1 Immunization Coverage (%) in Infants (2005 – 2015)
12.2 Global Immunization Profile (2011 – 2015)
12.3 Regional Immunization Profile (2001 – 2015)
12.3.1 Measles – Number of Cases Reported
12.3.2 Mumps – Number of Cases Reported
12.3.3 Rubella – Number of Cases Reported
12.3.4 Rubella (CRS) – Number of Cases Reported
12.3.5 Diphtheria – Number of Cases Reported
12.3.6 Tetanus (Neonatal) – Number of Cases Reported
12.3.7 Tetanus (Total) – Number of Cases Reported
12.3.8 Pertussis – Number of Cases Reported
12.3.9 Polio – Number of Cases Reported
12.3.10 Yellow Fever – Number of Cases Reported
12.3.11 Japanese encephalitis – Number of Cases Reported, 2006 - 2015
13 VACCINES KEY PLAYERS SALES AND FORECAST
13.1 GlaxoSmithKline, plc.’s Vaccines Sales and Forecast
13.2 Merck & Co. Vaccines Sales and Forecast
13.3 Sanofi Pasteur’s (France) Vaccines Sales and Forecast
13.4 Pfizer, Inc.’s Vaccines Sales and Forecast
13.5 Others Vaccines Sales and Forecast
14 VACCINES – PRODUCTS AND PIPELINE
14.1 GSK Vaccine Product Pipeline
14.2 Merck Vaccine Product Pipeline
14.3 Sanofi Vaccine Product Pipeline
14.4 Pfizer Vaccine Product Pipeline
15 TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY
16 VACCINES AND REGULATOR’S INTERVENTIONS
16.1 Making and Meeting Standards of Quality and Safety
16.2 Vaccine Funding
17 VACCINE MARKET DRIVERS
17.1 Inclusion in National Immunization Schedule
17.2 Growing Immunization Coverage for HPV Vaccines
17.3 Increase in Prevalence of Infectious Diseases
17.4 Global Immunization Vision and Strategy (GIVS)
17.5 GAVI Model Fuelling Vaccine Manufacturers
17.5.1 The Partnership Model
17.5.2 The Business Model
17.6 Increasing Vaccine Availability in United States
17.7 The Vaccine Safety Data link Project
17.8 The Vaccine Injury Compensation Program
17.9 Transforming of Vaccine Technologies
17.1 Global Vaccine Action Plan by WHO (2011 - 2020)
17.11 Continuous Focus on Effective Communication Strategies
18 VACCINES MARKET CHALLENGES
18.1 Hurdles to Optimal use of Licensed Vaccines
18.1.1 Technical Obstacles
18.1.2 Economic Obstacles
18.1.3 Cultural Obstacles
18.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
18.2.1 Legal Obstacles
18.2.2 General Technical Barriers
18.2.3 Economic Barriers
18.2.4 Regulatory Barriers
18.3 Shortening the Timeline for Vaccine Development
18.4 Refusal/Resistance to Vaccination
18.4.1 Vaccine Adverse Event Reporting System
18.5 Vaccine Shortages and Delays
18.6 Obstacles in Vaccine Research & Development
18.7 Barriers to New Entrants in the Vaccines Market
LISTS OF TABLES
Table 2-1: Vaccine Recommendations
Table 2-2: Other Recommended Vaccines
Table 3-1: Worldwide – Adult Vaccines Market Share (Percent), 2011 - 2016
Table 3-2: Worldwide – Adult Vaccines Market Share (Percent), 2017 - 2022
Table 5-1: Worldwide – Adult Immunized Share (Percent), 2011 - 2016
Table 5-2: Worldwide – Forecast for Adult Immunized Share (Percent), 2017 – 2022
Table 7-1: Worldwide – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2016
Table 7-2: Worldwide – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2017 - 2022
Table 12-1: Worldwide – Number of Reported Cases, 2011 – 2015
Table 12-2: Measles – Number of Cases Reported, 2001 – 2015
Table 12-3: Mumps – Number of Cases Reported, 2001 - 2015
Table 12-4: Rubella – Number of Cases Reported, 2001 - 2015
Table 12-5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015
Table 12-6: Diphtheria – Number of Cases Reported, 2001 - 2015
Table 12-7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015
Table 12-8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015
Table 12-9: Pertussis – Number of Cases Reported, 2001 - 2015
Table 12-10: Polio – Number of Cases Reported, 2001 - 2015
Table 12-11: Yellow Fever – Number of Cases Reported, 2001 - 2015
Table 12-12: Japanese encephalitis – Number of Cases Reported, 2006 - 2015
Table 14-1: Merck Vaccine Product Pipeline
Table 14-2: Sanofi Vaccine Product Pipeline
Table 14-3: Pfizer Vaccine Product Pipeline
Table 15-1: Vaccine Mergers & Acquisitions
Table 17-1: United States Immunization Schedule
Table 17-2: Afghanistan Immunization Schedule
Table 17-3: Norway Immunization Schedule
Table 17-4: India Immunization Schedule
Table 17-5: Vietnam Immunization Schedule
Table 17-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 17-7: Goal-Level Indicators, 2015 & 2020
Table 17-8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations
2 GLOBAL – ADULT VACCINES MARKET AND FORECAST
3 GLOBAL – ADULT VACCINES MARKET SHARE AND FORECAST
4 WORLDWIDE – ADULT IMMUNIZED NUMBERS AND FORECAST
5 WORLDWIDE – ADULT IMMUNIZED SHARE AND FORECAST
6 WORLDWIDE – DOSES OF ADULT VACCINES ADMINISTERED AND FORECAST
7 WORLDWIDE – DOSES OF VACCINES ADMINISTERED TO ADULT SHARE AND FORECAST
8 WORLDWIDE – VACCINE COMPANIES MARKET SHARE AND FORECAST
9 DISEASE WISE – ADULT VACCINES MARKET AND FORECAST
9.1 Influenza – Adult Vaccines Market and Forecast
9.2 Cervical Cancer (HPV) – Vaccines Market and Forecast
9.3 Zoster (Shingles) – Vaccines Market and Forecast
9.4 MMRV (Measles, Mumps, Rubella, and Varicella Vaccine) – Adult Vaccines Market and Forecast
9.5 Pneumococcal – Adult Vaccines Market and Forecast
9.6 Meningococcal – Adult Vaccines Market and Forecast
9.7 Hepatitis – Adult Vaccines Market and Forecast
9.8 TdaP – Adult Vaccines Market and Forecast
9.9 Travel and Miscellaneous – Vaccines Market and Forecast
10 DISEASE WISE – ADULT IMMUNIZED NUMBERS AND FORECAST
10.1 Influenza – Number of Adults Immunized and Forecast
10.2 Cervical Cancer (HPV) – People Immunized and Forecast
10.3 Zoster (Shingles) – Number of People Immunized and Forecast
10.4 MMRV – Number of Adults Immunized and Forecast
10.5 Pneumococcal – Number of Adults Immunized and Forecast
10.6 Meningococcal – Number of Adults Immunized and Forecast
10.7 Hepatitis – Number of Adults Immunized and Forecast
10.8 TdaP – Number of Adults Immunized and Forecast
11 DISEASE WISE – DOSES OF VACCINES ADMINISTERED AND FORECAST
11.1 Influenza – Doses of Adult Vaccines Administered and Forecast
11.2 Cervical Cancer (HPV) – Doses of Vaccines Administered and Forecast
11.3 Zoster (Shingles) – Doses of Vaccines Administered and Forecast
11.4 MMRV – Doses of Adult Vaccines Administered and Forecast
11.5 Pneumococcal – Doses of Adult Vaccines Administered and Forecast
11.6 Meningococcal – Doses of Adult Vaccines Administered and Forecast
11.7 Hepatitis – Doses of Adult Vaccines Administered and Forecast
11.8 TdaP – Doses of Adult Vaccines Administered and Forecast
12 DISEASE WISE - IMMUNIZATION PROFILE
12.1 Immunization Coverage (%) in Infants (2005 – 2015)
12.2 Global Immunization Profile (2011 – 2015)
12.3 Regional Immunization Profile (2001 – 2015)
12.3.1 Measles – Number of Cases Reported
12.3.2 Mumps – Number of Cases Reported
12.3.3 Rubella – Number of Cases Reported
12.3.4 Rubella (CRS) – Number of Cases Reported
12.3.5 Diphtheria – Number of Cases Reported
12.3.6 Tetanus (Neonatal) – Number of Cases Reported
12.3.7 Tetanus (Total) – Number of Cases Reported
12.3.8 Pertussis – Number of Cases Reported
12.3.9 Polio – Number of Cases Reported
12.3.10 Yellow Fever – Number of Cases Reported
12.3.11 Japanese encephalitis – Number of Cases Reported, 2006 - 2015
13 VACCINES KEY PLAYERS SALES AND FORECAST
13.1 GlaxoSmithKline, plc.’s Vaccines Sales and Forecast
13.2 Merck & Co. Vaccines Sales and Forecast
13.3 Sanofi Pasteur’s (France) Vaccines Sales and Forecast
13.4 Pfizer, Inc.’s Vaccines Sales and Forecast
13.5 Others Vaccines Sales and Forecast
14 VACCINES – PRODUCTS AND PIPELINE
14.1 GSK Vaccine Product Pipeline
14.2 Merck Vaccine Product Pipeline
14.3 Sanofi Vaccine Product Pipeline
14.4 Pfizer Vaccine Product Pipeline
15 TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY
16 VACCINES AND REGULATOR’S INTERVENTIONS
16.1 Making and Meeting Standards of Quality and Safety
16.2 Vaccine Funding
17 VACCINE MARKET DRIVERS
17.1 Inclusion in National Immunization Schedule
17.2 Growing Immunization Coverage for HPV Vaccines
17.3 Increase in Prevalence of Infectious Diseases
17.4 Global Immunization Vision and Strategy (GIVS)
17.5 GAVI Model Fuelling Vaccine Manufacturers
17.5.1 The Partnership Model
17.5.2 The Business Model
17.6 Increasing Vaccine Availability in United States
17.7 The Vaccine Safety Data link Project
17.8 The Vaccine Injury Compensation Program
17.9 Transforming of Vaccine Technologies
17.1 Global Vaccine Action Plan by WHO (2011 - 2020)
17.11 Continuous Focus on Effective Communication Strategies
18 VACCINES MARKET CHALLENGES
18.1 Hurdles to Optimal use of Licensed Vaccines
18.1.1 Technical Obstacles
18.1.2 Economic Obstacles
18.1.3 Cultural Obstacles
18.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
18.2.1 Legal Obstacles
18.2.2 General Technical Barriers
18.2.3 Economic Barriers
18.2.4 Regulatory Barriers
18.3 Shortening the Timeline for Vaccine Development
18.4 Refusal/Resistance to Vaccination
18.4.1 Vaccine Adverse Event Reporting System
18.5 Vaccine Shortages and Delays
18.6 Obstacles in Vaccine Research & Development
18.7 Barriers to New Entrants in the Vaccines Market
LISTS OF TABLES
Table 2-1: Vaccine Recommendations
Table 2-2: Other Recommended Vaccines
Table 3-1: Worldwide – Adult Vaccines Market Share (Percent), 2011 - 2016
Table 3-2: Worldwide – Adult Vaccines Market Share (Percent), 2017 - 2022
Table 5-1: Worldwide – Adult Immunized Share (Percent), 2011 - 2016
Table 5-2: Worldwide – Forecast for Adult Immunized Share (Percent), 2017 – 2022
Table 7-1: Worldwide – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2016
Table 7-2: Worldwide – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2017 - 2022
Table 12-1: Worldwide – Number of Reported Cases, 2011 – 2015
Table 12-2: Measles – Number of Cases Reported, 2001 – 2015
Table 12-3: Mumps – Number of Cases Reported, 2001 - 2015
Table 12-4: Rubella – Number of Cases Reported, 2001 - 2015
Table 12-5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015
Table 12-6: Diphtheria – Number of Cases Reported, 2001 - 2015
Table 12-7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015
Table 12-8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015
Table 12-9: Pertussis – Number of Cases Reported, 2001 - 2015
Table 12-10: Polio – Number of Cases Reported, 2001 - 2015
Table 12-11: Yellow Fever – Number of Cases Reported, 2001 - 2015
Table 12-12: Japanese encephalitis – Number of Cases Reported, 2006 - 2015
Table 14-1: Merck Vaccine Product Pipeline
Table 14-2: Sanofi Vaccine Product Pipeline
Table 14-3: Pfizer Vaccine Product Pipeline
Table 15-1: Vaccine Mergers & Acquisitions
Table 17-1: United States Immunization Schedule
Table 17-2: Afghanistan Immunization Schedule
Table 17-3: Norway Immunization Schedule
Table 17-4: India Immunization Schedule
Table 17-5: Vietnam Immunization Schedule
Table 17-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 17-7: Goal-Level Indicators, 2015 & 2020
Table 17-8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations
LIST OF FIGURES
Figure 2-1: Worldwide – Adult Vaccines Market (Billion US$), 2011 – 2016
Figure 2-2: Worldwide – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
Figure 4-1: Worldwide – Adult Immunized (Million), 2011 – 2016
Figure 4-2: Worldwide – Forecast for Adult Immunized (Million), 2017 – 2022
Figure 6-1: Worldwide – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 6-2: Worldwide – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 8-1: Worldwide – Key Players Vaccines Market Share (Percent), 2011 - 2016
Figure 8-2: Worldwide – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022
Figure 9-1: Influenza – Adult Vaccines Market (Billion US$), 2011 - 2016
Figure 9-2: Influenza – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
Figure 9-3: Cervical Cancer (HPV) – Vaccines Market (Billion US$), 2011 – 2016
Figure 9-4: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
Figure 9-5: Zoster (Shingles) – Vaccines Market (Billion US$), 2011 - 2016
Figure 9-6: Zoster (Shingles) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
Figure 9-7: MMRV – Adult Vaccines Market (Million US$), 2011 – 2016
Figure 9-8: MMRV – Forecast for Adult Vaccines Market (Million US$), 2017 – 2022
Figure 9-9: Pneumococcal – Adult Vaccines Market (Billion US$), 2011 - 2016
Figure 9-10: Pneumococcal – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
Figure 9-11: Areas with Frequent Epidemics of Meningococcal Meningitis
Figure 9-12: Meningococcal – Adult Vaccines Market (Million US$), 2011 – 2016
Figure 9-13: Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2017 - 2022
Figure 9-14: Hepatitis – Adult Vaccines Market (Billion US$), 2011 - 2016
Figure 9-15: Hepatitis – Forecast for Adult Vaccines Market (Billion US$), 2017 - 2022
Figure 9-16: TdaP – Adult Vaccines Market (Million US$), 2011 - 2016
Figure 9-17: TdaP – Forecast for Adult Vaccines Market (Million US$), 2017 - 2022
Figure 9-18: Travel and Miscellaneous – Vaccines Market (Billion US$), 2011 - 2016
Figure 9-19: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US$), 2017 - 2022
Figure 10-1: Influenza – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-2: Influenza – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-3: Cervical Cancer – Number of People Immunized (Thousand), 2011 - 2016
Figure 10-4: Cervical Cancer – Forecast for Number of People Immunized (Thousand), 2017 - 2022
Figure 10-5: Zoster (Shingles) – Number of People Immunized (Thousand), 2011 - 2016
Figure 10-6: Zoster (Shingles) – Forecast for Number of People Immunized (Thousand), 2017 - 2022
Figure 10-7: MMRV – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-8: MMRV – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-9: Pneumococcal – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-10: Pneumococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-11: Meningococcal – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-12: Meningococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-13: Hepatitis – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-14: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-15: TdaP – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-16: TdaP – Number of Adults Immunized (Thousand), 2017 - 2022
Figure 11-1: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-2: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-3: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2016
Figure 11-4: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
Figure 11-5: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2016
Figure 11-6: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
Figure 11-7: MMRV – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-8: MMRV – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-9: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-10: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-11: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-12: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-13: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-14: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-15: TdaP – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-16: TdaP – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 12-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Figure 12-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015
Figure 13-1: GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-2: Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-3: Merck & Co. Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-4: Forecast for Merck & Co. Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-5: Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2022
Figure 13-6: Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-7: Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-8: Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-9: Others Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-10: Forecast for Others Vaccines Sales (Billion US$), 2017 - 2022
Figure 14-1: GSK Vaccine Product Pipeline
Figure 17-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 17-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 17-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 17-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 17-5: US Retail Clinics Expected to Surge by 2017
Figure 2-1: Worldwide – Adult Vaccines Market (Billion US$), 2011 – 2016
Figure 2-2: Worldwide – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
Figure 4-1: Worldwide – Adult Immunized (Million), 2011 – 2016
Figure 4-2: Worldwide – Forecast for Adult Immunized (Million), 2017 – 2022
Figure 6-1: Worldwide – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 6-2: Worldwide – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 8-1: Worldwide – Key Players Vaccines Market Share (Percent), 2011 - 2016
Figure 8-2: Worldwide – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022
Figure 9-1: Influenza – Adult Vaccines Market (Billion US$), 2011 - 2016
Figure 9-2: Influenza – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
Figure 9-3: Cervical Cancer (HPV) – Vaccines Market (Billion US$), 2011 – 2016
Figure 9-4: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
Figure 9-5: Zoster (Shingles) – Vaccines Market (Billion US$), 2011 - 2016
Figure 9-6: Zoster (Shingles) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
Figure 9-7: MMRV – Adult Vaccines Market (Million US$), 2011 – 2016
Figure 9-8: MMRV – Forecast for Adult Vaccines Market (Million US$), 2017 – 2022
Figure 9-9: Pneumococcal – Adult Vaccines Market (Billion US$), 2011 - 2016
Figure 9-10: Pneumococcal – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
Figure 9-11: Areas with Frequent Epidemics of Meningococcal Meningitis
Figure 9-12: Meningococcal – Adult Vaccines Market (Million US$), 2011 – 2016
Figure 9-13: Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2017 - 2022
Figure 9-14: Hepatitis – Adult Vaccines Market (Billion US$), 2011 - 2016
Figure 9-15: Hepatitis – Forecast for Adult Vaccines Market (Billion US$), 2017 - 2022
Figure 9-16: TdaP – Adult Vaccines Market (Million US$), 2011 - 2016
Figure 9-17: TdaP – Forecast for Adult Vaccines Market (Million US$), 2017 - 2022
Figure 9-18: Travel and Miscellaneous – Vaccines Market (Billion US$), 2011 - 2016
Figure 9-19: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US$), 2017 - 2022
Figure 10-1: Influenza – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-2: Influenza – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-3: Cervical Cancer – Number of People Immunized (Thousand), 2011 - 2016
Figure 10-4: Cervical Cancer – Forecast for Number of People Immunized (Thousand), 2017 - 2022
Figure 10-5: Zoster (Shingles) – Number of People Immunized (Thousand), 2011 - 2016
Figure 10-6: Zoster (Shingles) – Forecast for Number of People Immunized (Thousand), 2017 - 2022
Figure 10-7: MMRV – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-8: MMRV – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-9: Pneumococcal – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-10: Pneumococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-11: Meningococcal – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-12: Meningococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-13: Hepatitis – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-14: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
Figure 10-15: TdaP – Number of Adults Immunized (Thousand), 2011 - 2016
Figure 10-16: TdaP – Number of Adults Immunized (Thousand), 2017 - 2022
Figure 11-1: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-2: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-3: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2016
Figure 11-4: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
Figure 11-5: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2016
Figure 11-6: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
Figure 11-7: MMRV – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-8: MMRV – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-9: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-10: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-11: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-12: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-13: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-14: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 11-15: TdaP – Doses of Adult Vaccines Administered (Million), 2011 - 2016
Figure 11-16: TdaP – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
Figure 12-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Figure 12-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015
Figure 13-1: GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-2: Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-3: Merck & Co. Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-4: Forecast for Merck & Co. Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-5: Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2022
Figure 13-6: Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-7: Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-8: Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-9: Others Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-10: Forecast for Others Vaccines Sales (Billion US$), 2017 - 2022
Figure 14-1: GSK Vaccine Product Pipeline
Figure 17-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 17-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 17-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 17-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 17-5: US Retail Clinics Expected to Surge by 2017
